Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Needle-safe rules safer still in Germany:

This article was originally published in Clinica

Executive Summary

Germany's technical regulation for biological materials, the so-called TRBA 250, has been strengthened again in a bid to provide maximum safety to staff who are exposed to needlestick injuries. The regulation has so far allowed employers to keep non-needle safe devices in circulation, provided that their other working practices guaranteed a minimisation of the risk of a sharps injury (see Clinica No 1266, p 6). Now, and with obvious implications for providers of autodisable devices, the federal workers' protection and medical staff institute (BAA) has decided that only safe devices can be used - except in patients who have a known negative disease status and from whom no blood-borne disease can be contracted. The view of the German accident insurance group (DGU) is that even routine blood draws should be done with needle-safe devices, obviating the need for hospitals to carry two device types.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT046337

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel